Oxford Global Conferences are proud to present the 2nd Annual Drug Discovery USA Congress, taking place on the 29th & 30th October at The Westin Boston Waterfront Hotel in Boston, USA. Our Congress brings together a host of senior level experts to discuss recent developments in the industry and debate the best strategies and solutions to improve drug discovery going forward.
The drug discovery landscape is changing rapidly. With the cost of bringing a drug to market rising rapidly, researchers are seeking innovative ways to increase the efficiency of their R&D pipelines. Our conference programme has been designed to address these challenges, and is composed of four interactive streams:
• Target Based Discovery
• Screening & Assays: Enabling Technologies
• Discovery Chemistry & Drug Design
• Supporting Innovation: Translational Approaches & Informatics Tools
On Day One our world-class speakers will tackle the big debates currently affecting research pipelines: should we prioritise phenotypic over target-based screening? How will we utilise discovery data later in the pipeline? How can we identify new targets after a phenotypic screen? In addition, our Congress will explore key research strategies such as repositioning existing drug products, approaches for targeting PPI and GPCRs and incorporating genomic technologies into discovery research.
On Day Two our Congress features an exciting stream dedicated to supporting innovation with informatics tools and will host discussions about the latest research in the discovery chemistry field. Our industry leaders will share case studies covering protein-protein interaction, water mediated binding, computational tools for drug design as well as fragment based drug design.
Delegates will also benefit from unparalleled networking opportunities. The two-day congress format combines dedicated networking breaks, pre-organised 1-2-1 meetings and our popular drinks reception. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion.
Visit our website to download the agenda: www.discoveryusa-congress.com
The drug discovery landscape is changing rapidly. With the cost of bringing a drug to market rising rapidly, researchers are seeking innovative ways to increase the efficiency of their R&D pipelines. Our conference programme has been designed to address these challenges, and is composed of four interactive streams:
• Target Based Discovery
• Screening & Assays: Enabling Technologies
• Discovery Chemistry & Drug Design
• Supporting Innovation: Translational Approaches & Informatics Tools
On Day One our world-class speakers will tackle the big debates currently affecting research pipelines: should we prioritise phenotypic over target-based screening? How will we utilise discovery data later in the pipeline? How can we identify new targets after a phenotypic screen? In addition, our Congress will explore key research strategies such as repositioning existing drug products, approaches for targeting PPI and GPCRs and incorporating genomic technologies into discovery research.
On Day Two our Congress features an exciting stream dedicated to supporting innovation with informatics tools and will host discussions about the latest research in the discovery chemistry field. Our industry leaders will share case studies covering protein-protein interaction, water mediated binding, computational tools for drug design as well as fragment based drug design.
Delegates will also benefit from unparalleled networking opportunities. The two-day congress format combines dedicated networking breaks, pre-organised 1-2-1 meetings and our popular drinks reception. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion.
Visit our website to download the agenda: www.discoveryusa-congress.com
